Acquisition by Tursi James Patrick of 5051 shares of Neurobo Pharmaceuticals subject to Rule 16b-3
| NRBODelisted Stock | USD 2.26 0.06 2.59% |
About 61% of Neurobo Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Neurobo Pharmaceuticals suggests that many traders are alarmed regarding Neurobo Pharmaceuticals' prospects. Neurobo Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Neurobo Pharmaceuticals. Many technical investors use Neurobo Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Neurobo |
Filed transaction by Neurobo Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at news.google.com
 |
Neurobo Pharmaceuticals Fundamental Analysis
We analyze Neurobo Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Neurobo Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurobo Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Neurobo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Neurobo Pharmaceuticals Related Equities
| CDIO | Cardio Diagnostics | 4.17 | ||||
| ATNF | 180 Life | 2.66 | ||||
| SONN | Sonnet Biotherapeutics | 1.69 | ||||
| ZURA | Zura Bio | 0.45 | ||||
| ALLR | Allarity Therapeutics | 1.90 | ||||
| BDRX | Biodexa Pharmaceticals | 2.03 | ||||
| PHIO | Phio Pharmaceuticals | 2.09 | ||||
| KPRX | Kiora Pharmaceuticals | 3.57 | ||||
| VRAX | Virax Biolabs | 8.82 | ||||
| QNRX | Quoin Pharmaceuticals | 10.40 | ||||
| REVB | Revelation Biosciences | 11.95 |
Check out Neurobo Pharmaceuticals Hype Analysis, Neurobo Pharmaceuticals Correlation and Neurobo Pharmaceuticals Performance. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |